BioWorld

Dec. 13, 2010

The Game of Risk: Mitigation, Funding, World Domination

The object of the military-themed board game might be total world domination, but in the biotech game of risk, just surviving can be tricky enough. Read More

Money Raised Year to Date

MMRC ASH Data Validate Better-Faster-Cheaper Trials

Cancer Drug Causes Cancer: Catastrophe or Minor Blip?

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

Phase I Clinical Trials Update: November 2010

Phase II Clinical Trials Update: November 2010

Phase III Clinical Trials Update: November 2010

American Association for the Study of Liver Diseases

American College of Rheumatology

American Heart Association

European Organisation for Research and Treatment of Cancer

Non-U.S. Clinical Trials & Regulatory Actions: Nov. 2010

FDA Submissions, Approvals & Other Actions: Nov. 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Viva in vivo! At EHA, in vivo CAR T data continues to impress

BioWorld

Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...